Phaseline

Companies › LAPIX Therapeutics

LAPIX Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LPX-TI641–Phase 1Atopic Dermatitis (AD); Rheumatoid Arthritis (RA)Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06982352LPX-TI641Phase 1Atopic Dermatitis (AD)ImmunologyJan 2026
NCT06628206LPX-TI641Phase 1Rheumatoid Arthritis (RA)ImmunologyNov 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.